Endocrine Complications of Immunotherapy and Targeted Cancer Therapy: A Critical Care Perspective

Dr Neeraj Manikath , Claude.ai

Abstract

Background: The advent of immune checkpoint inhibitors (ICIs) and targeted cancer therapies has revolutionized oncologic care, significantly improving survival outcomes across multiple malignancies. However, these agents carry unique toxicity profiles, particularly immune-related adverse events (irAEs) affecting the endocrine system. Endocrine irAEs can present with life-threatening complications requiring critical care management.

Objective: This review provides a comprehensive overview of endocrine complications associated with immunotherapy and targeted cancer therapy, with emphasis on pathophysiology, clinical presentation, diagnostic approaches, and management strategies relevant to critical care practitioners.

Methods: Literature review of peer-reviewed articles, clinical guidelines, and case series published between 2010-2024.

Results: Endocrine irAEs occur in 10-15% of patients receiving ICIs, with thyroid dysfunction being most common (6-50%), followed by adrenal insufficiency (1-5%), diabetes mellitus (1-2%), and hypophysitis (0.5-10%). Targeted therapies demonstrate distinct endocrine toxicity patterns depending on molecular targets.

Conclusions: Early recognition, prompt diagnosis, and appropriate management of endocrine irAEs are crucial for preventing life-threatening complications. Critical care physicians must maintain high clinical suspicion and implement systematic screening protocols.

Keywords: Immune checkpoint inhibitors, endocrine toxicity, immune-related adverse events, critical care, thyroiditis, adrenal insufficiency, diabetes mellitus, hypophysitis

Introduction

The landscape of cancer treatment has been fundamentally transformed by the introduction of immune checkpoint inhibitors (ICIs) and targeted therapies. These agents, including programmed death-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, have demonstrated remarkable efficacy across diverse malignancies¹. However, their mechanism of action—unleashing the immune system against cancer cells—inevitably leads to immune-related adverse events (irAEs) that can affect virtually any organ system².

Endocrine irAEs represent a particularly challenging subset of complications, occurring in 10-15% of patients receiving ICIs³. Unlike traditional chemotherapy-induced toxicities, endocrine irAEs often present insidiously, may be irreversible, and can progress to life-threatening endocrine crises requiring intensive care management. The spectrum includes thyroid disorders, adrenal insufficiency, type 1 diabetes mellitus, hypophysitis, and less commonly, hypoparathyroidism and gonadal dysfunction⁴.

Critical care physicians increasingly encounter these complications as ICI use expands across oncologic indications. This review aims to provide practical guidance for recognition, diagnosis, and management of endocrine irAEs in the critical care setting, emphasizing pearls and pitfalls that can impact patient outcomes.

Pathophysiology of Endocrine Immune-Related Adverse Events

Mechanisms of Immune Checkpoint Disruption

Immune checkpoints serve as regulatory mechanisms preventing excessive immune activation and autoimmunity. PD-1/PD-L1 and CTLA-4 pathways normally provide inhibitory signals to T-cells, maintaining immune homeostasis⁵. ICIs block these pathways, enhancing anti-tumor immunity but simultaneously predisposing to autoimmune phenomena.

The endocrine system appears particularly susceptible to irAEs due to several factors:

High expression of checkpoint proteins in endocrine tissues
Molecular mimicry between tumor antigens and endocrine proteins
Pre-existing subclinical autoimmunity
Genetic predisposition (HLA associations)⁶

Temporal Patterns and Risk Factors

Endocrine irAEs demonstrate distinct temporal patterns:

Thyroiditis: Typically occurs within 6-12 weeks of treatment initiation
Hypophysitis: Usually develops within 2-4 months, more common with CTLA-4 inhibitors
Adrenal insufficiency: Can occur at any time, often secondary to hypophysitis
Type 1 diabetes: Variable timing, may occur months to years after initiation⁷

🔍 Clinical Pearl: Unlike traditional endocrine disorders, ICI-induced endocrinopathies often present with atypical symptoms that may be attributed to cancer progression or other treatments, leading to delayed diagnosis.

Checkpoint Inhibitor-Induced Thyroiditis

Epidemiology and Clinical Spectrum

Thyroid dysfunction represents the most common endocrine irAE, affecting 6-50% of patients depending on the specific ICI regimen⁸. The clinical spectrum includes:

Thyrotoxicosis phase (destructive thyroiditis)
Hypothyroid phase (often permanent)
Isolated hypothyroidism (de novo)
Isolated thyrotoxicosis (rare, usually Graves-like)

Pathophysiology

ICI-induced thyroiditis typically follows a destructive pattern similar to silent thyroiditis, characterized by:

Lymphocytic infiltration of thyroid tissue
Destruction of thyroid follicles
Release of preformed thyroid hormones
Eventual progression to hypothyroidism⁹

Clinical Presentation

Thyrotoxic Phase:

Palpitations, tremor, heat intolerance
Weight loss, anxiety, insomnia
Atrial fibrillation (15-20% of cases)
Thyroid storm (rare but life-threatening)

Hypothyroid Phase:

Fatigue, weight gain, cold intolerance
Depression, cognitive impairment
Myxedema coma (extremely rare)

⚠️ Clinical Oyster: Thyrotoxic symptoms may be masked by beta-blockers used for cardiovascular comorbidities, leading to missed diagnosis until progression to hypothyroidism.

Diagnostic Approach

Laboratory Evaluation:

TSH, free T4, free T3
Thyroglobulin (elevated in destructive thyroiditis)
Thyroid peroxidase antibodies (TPO-Ab)
Thyroglobulin antibodies (Tg-Ab)
TSH receptor antibodies (TRAb) if Graves disease suspected

Imaging:

Thyroid ultrasound: hypoechoic, heterogeneous pattern
Radioiodine uptake scan: low/absent uptake in destructive thyroiditis
18F-FDG PET: increased uptake may indicate thyroiditis¹⁰

💡 Management Hack: In critically ill patients, consider point-of-care thyroid ultrasound to rapidly assess for thyroiditis—look for diffusely hypoechoic, heterogeneous echotexture with increased vascularity.

Management Strategies

Thyrotoxic Phase:

Beta-blockers for symptom control
Avoid antithyroid drugs (ineffective in destructive thyroiditis)
Corticosteroids for severe cases (prednisone 1-2 mg/kg/day)
Monitor for atrial fibrillation and heart failure

Hypothyroid Phase:

Levothyroxine replacement (1.6 μg/kg/day)
Dose adjustment based on TSH levels
Consider higher initial doses in critically ill patients
Lifetime replacement usually required

Thyroid Storm Management:

High-dose beta-blockers (propranolol 80-120 mg q6h)
Corticosteroids (hydrocortisone 300 mg q8h)
Supportive care (cooling, fluid resuscitation)
Plasmapheresis in refractory cases¹¹

Checkpoint Inhibitor-Induced Adrenal Insufficiency

Types and Mechanisms

Primary Adrenal Insufficiency:

Direct immune-mediated destruction of adrenal cortex
Rare (<1% of patients)
Often irreversible

Secondary Adrenal Insufficiency:

More common, secondary to hypophysitis
ACTH deficiency
May be reversible with time¹²

Clinical Presentation

Acute Adrenal Crisis:

Hypotension, shock
Nausea, vomiting, abdominal pain
Altered mental status
Hyponatremia, hyperkalemia
Hypoglycemia

Chronic Adrenal Insufficiency:

Fatigue, weakness
Weight loss, anorexia
Orthostatic hypotension
Hyperpigmentation (primary AI only)

⚠️ Critical Oyster: Adrenal crisis may be precipitated by physiologic stress (infection, surgery) and can be the presenting feature of ICI-induced adrenal insufficiency.

Diagnostic Evaluation

Laboratory Tests:

Morning cortisol (<3 μg/dL suggests AI, >15 μg/dL excludes AI)
ACTH (high in primary AI, low/normal in secondary AI)
Cosyntropin stimulation test (peak cortisol <18-20 μg/dL abnormal)
Electrolytes (hyponatremia, hyperkalemia in primary AI)
Glucose (hypoglycemia may occur)

Additional Tests:

21-hydroxylase antibodies (positive in autoimmune primary AI)
Aldosterone and renin (affected only in primary AI)
Pituitary MRI if secondary AI suspected¹³

💡 Diagnostic Hack: In critically ill patients, random cortisol <10 μg/dL or inadequate response to stress (cortisol <25 μg/dL during critical illness) suggests relative adrenal insufficiency warranting steroid supplementation.

Management

Acute Adrenal Crisis:

Immediate steroid replacement:
- Hydrocortisone 100 mg IV bolus
- Hydrocortisone 50-100 mg IV q6-8h or continuous infusion
Fluid resuscitation:
- Normal saline 1-2 L rapidly
- Monitor for fluid overload
Electrolyte correction:
- Monitor and correct hyponatremia gradually
- Hyperkalemia usually corrects with steroid replacement
Treat precipitating factors

Chronic Replacement:

Hydrocortisone 15-25 mg daily (divided doses)
Fludrocortisone 0.05-0.2 mg daily (primary AI only)
Stress dose education (double/triple doses during illness)
Medical alert identification¹⁴

🔧 Management Hack: Use hydrocortisone rather than dexamethasone for suspected adrenal crisis, as dexamethasone interferes with cortisol assays and lacks mineralocorticoid activity.

Checkpoint Inhibitor-Induced Diabetes Mellitus

Characteristics and Pathophysiology

ICI-induced diabetes mellitus typically manifests as fulminant type 1 diabetes characterized by:

Rapid onset (days to weeks)
Severe insulin deficiency
High risk of diabetic ketoacidosis (DKA)
Often low C-peptide levels
Variable presence of diabetes autoantibodies¹⁵

The mechanism involves T-cell-mediated destruction of pancreatic β-cells, similar to classic type 1 diabetes but with accelerated progression.

Clinical Presentation

Acute Presentation:

Diabetic ketoacidosis (50-70% of cases)
Polyuria, polydipsia, weight loss
Nausea, vomiting, abdominal pain
Altered mental status
Kussmaul respirations

⚠️ Critical Pearl: ICI-induced diabetes often presents with DKA as the initial manifestation, unlike typical type 1 diabetes which usually has a prodromal phase.

Diagnostic Approach

Laboratory Evaluation:

Glucose (often >400 mg/dL at presentation)
Arterial blood gas (metabolic acidosis, pH <7.30)
Ketones (serum β-hydroxybutyrate >3.0 mmol/L)
C-peptide (typically low)
HbA1c (may be normal if rapid onset)

Diabetes Autoantibodies:

Anti-GAD antibodies
Anti-IA2 antibodies
Anti-ZnT8 antibodies
Insulin autoantibodies (if insulin-naïve)¹⁶

Management

Diabetic Ketoacidosis:

Fluid resuscitation:
- Normal saline 15-20 mL/kg/h initially
- Switch to half-normal saline when glucose <250 mg/dL
Insulin therapy:
- Regular insulin 0.1 units/kg/h IV (after initial bolus)
- Adjust rate to decrease glucose by 50-70 mg/dL/h
Electrolyte monitoring:
- Frequent potassium monitoring and replacement
- Phosphate replacement if <1.0 mg/dL
Bicarbonate therapy:
- Consider if pH <7.0 or bicarbonate <5 mEq/L

Long-term Management:

Intensive insulin therapy required
Continuous glucose monitoring recommended
Diabetes education and nutritional counseling
Regular monitoring for diabetic complications¹⁷

💡 Treatment Hack: Start dextrose-containing fluids when glucose falls below 250 mg/dL to prevent hypoglycemia while continuing insulin to clear ketones.

Checkpoint Inhibitor-Induced Hypophysitis

Epidemiology and Risk Factors

Hypophysitis occurs in 0.5-10% of patients receiving ICIs, with higher incidence associated with:

CTLA-4 inhibitors (especially ipilimumab)
Combination ICI therapy
Male gender
Pre-existing pituitary pathology¹⁸

Clinical Presentation

Acute Symptoms:

Severe headache
Visual field defects
Nausea, vomiting
Altered mental status
Symptoms of hormone deficiencies

Hormone Deficiency Patterns:

ACTH deficiency (most common)
TSH deficiency
LH/FSH deficiency
Growth hormone deficiency
Antidiuretic hormone deficiency (rare)¹⁹

Diagnostic Evaluation

Laboratory Tests:

Comprehensive pituitary function testing:
- ACTH, cortisol
- TSH, free T4
- LH, FSH, testosterone/estradiol
- Prolactin
- IGF-1

Imaging:

MRI pituitary with gadolinium:
- Pituitary enlargement
- Heterogeneous enhancement
- Possible mass effect
Follow-up imaging to monitor resolution²⁰

Dynamic Testing:

Cosyntropin stimulation test
Insulin tolerance test (if safe)
GH stimulation tests

Management

Acute Management:

Corticosteroid replacement (primary consideration)
Monitor for adrenal crisis
Assess for mass effect symptoms

Hormone Replacement:

Glucocorticoid replacement:
- Hydrocortisone 15-25 mg daily
- Stress dose protocols
Thyroid hormone replacement:
- Levothyroxine (after glucocorticoid replacement)
Sex hormone replacement:
- Testosterone or estrogen/progesterone as appropriate
ADH replacement (if needed):
- Desmopressin for diabetes insipidus²¹

🔍 Clinical Pearl: Always replace glucocorticoids before thyroid hormone to prevent precipitation of adrenal crisis.

Targeted Therapy-Induced Endocrine Complications

Tyrosine Kinase Inhibitors (TKIs)

Thyroid Dysfunction:

Mechanism: Decreased thyroid hormone synthesis, increased clearance
Prevalence: 20-85% depending on specific TKI
Management: Levothyroxine replacement, TSH monitoring

Adrenal Insufficiency:

Less common than with ICIs
Usually reversible upon discontinuation
May require temporary steroid replacement²²

mTOR Inhibitors

Hyperglycemia:

Insulin resistance and decreased insulin secretion
Dose-dependent effect
Management: Metformin, insulin as needed

Hyperlipidemia:

Common side effect
Requires statin therapy in many patients²³

CDK4/6 Inhibitors

Thyroid Dysfunction:

Hypothyroidism reported
Mechanism unclear
Usually mild and manageable

Critical Care Management Pearls and Oysters

🔍 Clinical Pearls

High Index of Suspicion:
- Consider endocrine irAEs in any patient receiving ICIs with unexplained fatigue, altered mental status, or hemodynamic instability
Baseline Screening:
- Obtain baseline TSH, free T4, morning cortisol, glucose, HbA1c before ICI initiation
- Repeat every 4-6 weeks during first 6 months
Stress Dosing:
- Any patient with known adrenal insufficiency requires stress dose steroids for critical illness, procedures, or surgery
Thyroid Storm Recognition:
- Fever, tachycardia, altered mental status in setting of recent thyrotoxicosis
- High mortality if untreated

⚠️ Clinical Oysters (Pitfalls)

Normal TSH with Hypophysitis:
- Central hypothyroidism may present with normal or low-normal TSH
- Always check free T4 in suspected hypophysitis
Masked Adrenal Crisis:
- Symptoms may be attributed to sepsis or other critical illness
- Low threshold for cosyntropin stimulation test
DKA without Known Diabetes:
- ICI-induced diabetes often presents with DKA as first manifestation
- Consider in any ICI patient with unexplained metabolic acidosis
Steroid Dependency:
- Some endocrine irAEs may be irreversible
- Avoid premature steroid withdrawal

🔧 Management Hacks

Point-of-Care Testing:
- Bedside glucose monitoring for early diabetes detection
- POC cortisol if available for rapid assessment
Empiric Treatment:
- Consider empiric steroids in suspected adrenal crisis while awaiting test results
- Don't delay treatment for confirmatory testing in unstable patients
Multidisciplinary Approach:
- Early endocrinology consultation
- Close coordination with oncology team
- Consider continuing immunotherapy if irAE manageable

Monitoring and Long-term Outcomes

Surveillance Protocols

Pre-treatment Evaluation:

Complete endocrine history and examination
Baseline laboratory studies
Screening for autoimmune diseases

During Treatment:

Regular monitoring every 4-6 weeks initially
More frequent monitoring if symptoms develop
Patient education on warning signs

Post-treatment:

Lifelong monitoring for delayed irAEs
Some endocrinopathies may appear months after discontinuation²⁴

Reversibility and Prognosis

Generally Irreversible:

Thyroid dysfunction (>95% permanent)
Type 1 diabetes (>95% permanent)
Primary adrenal insufficiency

Potentially Reversible:

Secondary adrenal insufficiency (30-50% recovery)
Hypophysitis (partial recovery in some patients)²⁵

Future Directions and Research

Predictive Biomarkers

Research focuses on identifying patients at highest risk for endocrine irAEs:

Genetic markers (HLA associations)
Baseline autoantibodies
Immune profiling

Novel Therapeutic Approaches

Selective immunosuppression strategies
Preventive interventions
Improved hormone replacement therapies²⁶

Combination Therapy Considerations

As combination immunotherapy becomes more common, understanding the cumulative risk and management of endocrine complications becomes increasingly important.

Conclusions

Endocrine complications of immunotherapy and targeted cancer therapy represent a growing challenge in critical care medicine. Key principles for optimal management include:

Maintain high clinical suspicion for endocrine irAEs in patients receiving these therapies
Implement systematic screening protocols with regular monitoring
Recognize that early intervention can prevent life-threatening complications
Understand that many endocrinopathies are irreversible and require lifelong management
Coordinate care closely with oncology and endocrinology specialists
Educate patients and families about warning signs and emergency management

As the use of ICIs and targeted therapies continues to expand, critical care physicians must be prepared to diagnose and manage these complex endocrine complications promptly and effectively.

References

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168.
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768.
Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173-182.
de Filette J, Jansen Y, Schreuer M, et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab. 2016;101(11):4431-4439.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21(2):371-381.
Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17(7):389-399.
Illouz F, Braun D, Briet C, Schweizer U, Rodien P. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol. 2014;171(3):R91-99.
Delivanis DA, Gustafson MP, Bornschlegl S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 2017;102(8):2770-2780.
Yamauchi I, Sakane Y, Fukuda Y, et al. Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid. 2017;27(7):894-901.
Akturk HK, Alkanani A, Rewers A, et al. Metformin-induced lactic acidosis associated with acute kidney injury. Nat Rev Endocrinol. 2018;14(1):63-64.
Berdelou A, Lamartina L, Klain M, Leboulleux S, Schlumberger M. Treatment of refractory thyroid cancer. Endocr Relat Cancer. 2018;25(4):R209-223.
Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13(4):195-207.
Husebye ES, Pearce SH, Krone NP, Kämpe O. Adrenal insufficiency. Lancet. 2021;397(10274):613-629.
Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471-1480.
Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2019;36(9):1075-1081.
American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15-S33.
Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99(11):4078-4085.
Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016;186(12):3225-3235.
Albarel F, Gaudy C, Castinetti F, et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172(2):195-204.
Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3888-3921.
Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol. 2016;28(4):278-287.
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
Patel NS, Oury A, Daniels GA, et al. Incidence of thyroid dysfunction in patients with relapsed refractory multiple myeloma treated with single-agent pembrolizumab. Hematol Oncol. 2019;37(3):262-267.
Min L, Hodi FS, Giobbie-Hurder A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015;21(4):749-755.
June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-1365.

Saturday, August 23, 2025